Billing and Coding: MolDX: BCR-ABL

MolDX billing guidance for BCR-ABL testing requires use of CPT 81479 to report multiple tests assigned a single MolDX ID and mandates CPT 81479 plus one (1) UOS and the assigned DEX Z-code for NGS-based BCR-ABL translocation analysis. The FDA-approved MRDx BCR-ABL test is reported with CPT 0040U, and ABL1 kinase domain mutation analysis for acquired imatinib resistance is reported with CPT 81170 plus one (1) UOS and the assigned DEX Z-code; CPT 81206/81207/81208 are only reportable under the MolDX-specified single-test conditions.

"When multiple tests are assigned a single MolDX ID, submit CPT 81479 to report the combined test."

Sign up to see full coverage criteria, indications, and limitations.